Dr. Mahley, along with Gladstone Investigator Yadong Huang, MD, PhD, will use the funding to identify new chemical compounds that can target apolipoprotein E4 (apoE4)-- the strongest genetic risk factor for developing Alzheimer's.
E-Scape Bio is now developing small - molecule drugs that target the primary genetic cause of Alzheimer's disease by correcting adverse effects of the apolipoprotein E4 (apoE4) gene.